All In Biotech

Drug Trial Radar · NCT01816594

NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer

NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

50

Actual

Start

Sep 3, 2013

Primary completion

Feb 18, 2015

Study completion Feb 18, 2015

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
Collaborators
Breast International Group; GBG Forschungs GmbH; SOLTI Breast Cancer Research Group
First posted
Mar 22, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, parallel cohort, two stage, double-blind, placebo-controlled study evaluated the oral PI3K inhibitor BKM120 in combination with trastuzumab and paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer prior to surgery (neo-adjuvant setting).

Conditions

  • HER2-positive Newly Diagnosed, Primary Breast Cancer

Interventions

  • BKM120Drug

    Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.

  • TrastuzumabDrug

    Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.

  • PaclitaxelDrug

    Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.

  • BKM120 PlaceboDrug

    Neoadjuvant BKM120 placebo Administered orally 100 mg/day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological Complete Response (pCR) Rate at the Time of Surgery - All ParticipantsTime frame: After 6 weeks
  2. Pathological Complete Response (pCR) Rate at the Time of Surgery - PIK3CA Wild Type (WT)Time frame: After 6 weeks
  3. Pathological Complete Response (pCR) Rate at the Time of Surgery - PIK3CA Mutant (MT)Time frame: After 6 weeks

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Lübeck, Germany

  • Novartis Investigative Site

    Offenbach, Germany

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Seville, Andalusia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.